Biora Therapeutics (BIORQ)
OTHER OTC:BIORQ
Top Page
No summary available
Positive Factors
Revenue Growth
The significant revenue growth indicates a strong potential for market expansion and product adoption, which can drive future profitability and enhance competitive positioning in the biotechnology sector.
Negative Factors
High Leverage
A highly leveraged balance sheet with negative equity increases financial risk, potentially leading to solvency issues and limiting the company's flexibility to navigate market challenges or invest in new opportunities.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The significant revenue growth indicates a strong potential for market expansion and product adoption, which can drive future profitability and enhance competitive positioning in the biotechnology sector.
Read all positive factors
Biora Therapeutics (BIORQ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.00
Dividend YieldN/A
Average Volume (3M)9.55K
Price to Earnings (P/E)―
Beta (1Y)-28.49
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees58
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,522,702
10 Day Avg. Volume3,203
30 Day Avg. Volume9,551
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.17
Price to Sales (P/S)573.04
P/FCF Ratio0.57
Enterprise Value/Market Cap6.44M
Enterprise Value/Revenue18.26
Enterprise Value/Gross Profit48.44
Enterprise Value/Ebitda-1.34
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Biora Therapeutics Business Overview & Revenue Model
Company Description
Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to...
How the Company Makes Money
Biora Therapeutics makes money primarily through the development and commercialization of its proprietary drug delivery platforms and therapeutics. The company generates revenue by partnering with other pharmaceutical companies to co-develop produ...
Biora Therapeutics Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.76M | 4.00K | 305.00K | 1.25M | 74.31M | 143.99M |
| Gross Profit | 665.00K | 4.00K | 305.00K | 1.25M | -19.12M | 43.49M |
| EBITDA | -24.06M | -114.05M | -37.35M | -164.57M | -106.18M | -135.44M |
| Net Income | -31.54M | -124.11M | -38.16M | -178.52M | -192.53M | -148.04M |
Balance Sheet | ||||||
| Total Assets | 14.51M | 31.21M | 53.52M | 108.84M | 154.44M | 101.73M |
| Cash, Cash Equivalents and Short-Term Investments | 3.20M | 15.21M | 30.49M | 88.40M | 92.08M | 33.04M |
| Total Debt | 39.65M | 47.43M | 129.31M | 126.40M | 160.54M | 73.37M |
| Total Liabilities | 121.13M | 132.64M | 155.81M | 193.81M | 261.43M | 185.60M |
| Stockholders Equity | -106.63M | -101.42M | -102.29M | -84.98M | -106.99M | -83.87M |
Cash Flow | ||||||
| Free Cash Flow | -5.50M | -48.60M | -65.21M | -168.34M | -170.69M | -109.85M |
| Operating Cash Flow | -5.37M | -48.50M | -64.42M | -167.49M | -165.74M | -106.12M |
| Investing Cash Flow | 5.28M | 2.44M | -792.00K | -1.24M | -4.94M | 16.52M |
| Financing Cash Flow | 31.27M | 30.78M | 7.30M | 165.05M | 229.72M | 73.64M |
Biora Therapeutics Technical Analysis
Negative
0.12
Price Trends
0.17
Negative
0.16
Negative
0.70
Negative
Market Momentum
-0.02
Positive
35.33
Neutral
4.82
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIORQ, the sentiment is Negative. The current price of 0.12 is below the 20-day moving average (MA) of 0.20, below the 50-day MA of 0.17, and below the 200-day MA of 0.70, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 35.33 is Neutral, neither overbought nor oversold. The STOCH value of 4.82 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BIORQ.
Biora Therapeutics Risk Analysis
Biora Therapeutics disclosed 68 risk factors in its most recent earnings report. Biora Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Biora Therapeutics Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
| ― | $5.00 | ― | 29.58% | ― | ― | ― | |
50 Neutral | $190.05M | 5.44 | -21.16% | ― | -92.42% | 62.37% | |
46 Neutral | $42.50M | -0.71 | -80.00% | ― | ― | 9.63% | |
44 Neutral | $5.15M | -0.28 | -203.36% | ― | ― | 90.53% | |
43 Neutral | $3.47M | -0.15 | -381.74% | ― | ― | 98.22% | |
43 Neutral | $3.81M | -0.12 | -215.04% | ― | -100.00% | 93.82% |
* General Sector Average
BIORQ
Biora Therapeutics
0.12
0.00
0.00%
SNSE
Sensei Biotherapeutics
31.71
25.40
402.22%
GRI
GRI Bio
2.40
-31.48
-92.92%
SABS
SAB Biotherapeutics
3.73
2.55
216.10%
DRMA
Dermata Therapeutics
1.28
-6.60
-83.76%
AZTR
Azitra Inc
0.24
-1.63
-87.39%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―